AKBA Stock Overview
A biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 5/6 |
Past Performance | 0/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
Akebia Therapeutics, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$1.15 |
52 Week High | US$2.48 |
52 Week Low | US$0.78 |
Beta | 0.93 |
1 Month Change | -15.44% |
3 Month Change | -20.69% |
1 Year Change | -0.86% |
3 Year Change | -67.05% |
5 Year Change | -78.05% |
Change since IPO | -95.69% |
Recent News & Updates
Recent updates
Akebia's Vafseo Faces Grim Market Outlook (Rating Downgrade)
Apr 02There's No Escaping Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Muted Revenues Despite A 30% Share Price Rise
Mar 19Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Share Price Boosted 31% But Its Business Prospects Need A Lift Too
Jan 05Positive Sentiment Still Eludes Akebia Therapeutics, Inc. (NASDAQ:AKBA) Following 27% Share Price Slump
Jun 23Is Akebia Therapeutics (NASDAQ:AKBA) Using Debt Sensibly?
Mar 02Akebia Therapeutics: FDA Approval Failure, Terminated Partnerships, And Looming LOE - Too Risky
Oct 07Broker Revenue Forecasts For Akebia Therapeutics, Inc. (NASDAQ:AKBA) Are Surging Higher
Aug 10Akebia regains rights to kidney disease therapy after termination of deals with Otsuka
Jun 30Another Look At Akebia Therapeutics
Sep 06Is Akebia Therapeutics (NASDAQ:AKBA) Using Debt In A Risky Way?
Jun 24Akebia wins $40M Department of Veterans Affairs contract
Jun 15FDA accepts Akebia's vadadustat NDA for review
Jun 01Should Shareholders Reconsider Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) CEO Compensation Package?
May 26Akebia EPS misses by $0.08, beats on revenue
May 10Shareholder Returns
AKBA | US Biotechs | US Market | |
---|---|---|---|
7D | -5.0% | 3.2% | 1.7% |
1Y | -0.9% | 6.2% | 26.3% |
Return vs Industry: AKBA underperformed the US Biotechs industry which returned 6% over the past year.
Return vs Market: AKBA underperformed the US Market which returned 26.3% over the past year.
Price Volatility
AKBA volatility | |
---|---|
AKBA Average Weekly Movement | 14.1% |
Biotechs Industry Average Movement | 11.1% |
Market Average Movement | 5.9% |
10% most volatile stocks in US Market | 16.0% |
10% least volatile stocks in US Market | 2.8% |
Stable Share Price: AKBA's share price has been volatile over the past 3 months.
Volatility Over Time: AKBA's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2007 | 167 | John Butler | www.akebia.com |
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company’s lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis.
Akebia Therapeutics, Inc. Fundamentals Summary
AKBA fundamental statistics | |
---|---|
Market cap | US$240.78m |
Earnings (TTM) | -US$43.03m |
Revenue (TTM) | US$187.23m |
1.3x
P/S Ratio-5.6x
P/E RatioIs AKBA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
AKBA income statement (TTM) | |
---|---|
Revenue | US$187.23m |
Cost of Revenue | US$31.32m |
Gross Profit | US$155.90m |
Other Expenses | US$198.94m |
Earnings | -US$43.03m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.21 |
Gross Margin | 83.27% |
Net Profit Margin | -22.99% |
Debt/Equity Ratio | -306.9% |
How did AKBA perform over the long term?
See historical performance and comparison